The Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) study showed the benefit of canakinumab, an IL-1β blockade, in patients with previous myocardial infarction [144]. This evidence concerns the gene IL1B and myocardial infarction.